[Correspondence] Stakeholder collaboration for spinal muscular atrophy therapy development
In a 2016 Policy View,1 we highlighted the importance of collaborative efforts and a constructive dialogue among patient representatives, academics, industry, and regulators for streamlining new therapy development in rare diseases, using the example of Duchenne muscular dystrophy. This approach was applied to the field of spinal muscular atrophy (SMA) in a stakeholder meeting recently co-organized by SMA Europe, the European Medicines Agency, and the TREAT-NMD alliance.
Keith Vossel is an Associate Professor in the N Bud Grossman Center for Memory Research and Care, Institute for Translational Neuroscience, and the Department of Neurology at the University of Minnesota, Minneapolis, MN, USA. In addition to caring for patients, he investigates antiepileptic and tau-based therapies to treat network dysfunction in Alzheimer's disease.
[In Context] Neuropathies and diabetes in Jules Verne
The French writer Jules Gabriel Verne (1828–1905) was affected by various illnesses. As a young man, he had five episodes of Bell's palsy.1 He developed type 2 diabetes in his fifties,2 which, when his nephew Gaston shot him in the left ankle on March 9, 1886, complicated the healing of the wound. A secondary infection left him with a pronounced limp until his death.2
[Correspondence] Diagnosis and treatment of carpal tunnel syndrome
While I believe that the Review by Luca Padua and colleagues1 can be useful for many health-care professionals, an excellent analysis of the available evidence regarding carpal tunnel syndrome2 was not included. Hand surgeons will approach this disease in a slightly different manner than Padua and colleagues do. From a surgeon's perspective, each of the non-surgical management strategies described by the authors can be considered a low risk, but also a low benefit approach, with any improvement in symptoms likely transient in nature, and possibly related to placebo effect.
[Correspondence] Cognitive decline before diagnosis of Parkinson's disease
Anette Schrag and colleagues1 assessed the usefulness of several demographic, clinical, and biomarker variables to predict cognitive impairment in patients with newly diagnosed Parkinson's disease, and systematically selected the best predictors to construct a prediction model. The study provides important hints about the underlying mechanisms of cognitive decline in Parkinson's disease.
[Review] Epileptic activity in Alzheimer's disease: causes and clinical relevance
Epileptic activity is frequently associated with Alzheimer's disease; this association has therapeutic implications, because epileptic activity can occur at early disease stages and might contribute to pathogenesis. In clinical practice, seizures in patients with Alzheimer's disease can easily go unrecognised because they usually present as non-motor seizures, and can overlap with other symptoms of the disease. In patients with Alzheimer's disease, seizures can hasten cognitive decline, highlighting the clinical relevance of early recognition and treatment.
Jensen RH. The most important advances in headache research in 2016. Lancet Neurol 2017; 16: 5–7—In this Round-up Comment, the conflicts of interest statement was missing. This statement has been added to the online version as of March 14, 2017.